Centre for Biochemical Sensors Translational Pipeline

The Centre for Biochemical Sensors is uniquely suited to conduct research that moves advanced technology from invention through fabrication, animal studies, regulatory approval, and clinical trials. This translational pipeline is unique in academia, integrating many concepts and processes that are more commonly found in industry. The output of this infrastructure allows all medical devices developed in the lab to be produced to a high quality standard with complete design history documentation. This level of advanced device development facilitates interactions with industry and accelerates the clinical translation of the sensing technologies developed in the lab.

Translational technologies commercialised in Yetisen lab

1. BenchMark ULTRA IHC/ISH System (Hoffmann-La Roche)

The BenchMark ULTRA system is Roche Tissue Diagnostics’ most innovative, fully-automated immunohistochemistry and in situ hybridization slide staining system, offering multiple features designed to deliver diagnostic confidence to histopathology laboratories worldwide — the most notable of which are the individual slide drawers that support single piece workflow. This fully automated instrument offers 30 independent slide drawers and single-piece workflow — supporting the largest menu of 250+ ready-to-use assays. (Cell staining with air quenched steam heating, WO Patent Application WO/2011/139976, 2011Visit BenchMark ULTRA Website

2. Smartphone Diagnostic Reader (Colorimetrix GmbH)

This technology turn any smartphone into a portable spectrophotometer by using its camera and a mathematical algorithm. This way we read and interpret concentration values of the substances we measure on any colorimetric test (strips, dipsticks, lateral-flow tests, microplates, solution based assays). Visit Colorimetrix Website

3. Electronic Stents

We invented a gastrointestinal stent including an integrated circuit, a wireless power receiver and an accumulator for energy storage, which are coated with a polymer layer such as polytetrafluoroethylene or silicon to provide biocompatibility. The stent has the capability to provide hyperthermia therapy, light and photodynamic therapy, electrostimulation, drug delivery, and sense physical parameters and physiological analytes with a minimal risk of stent migration. (Stent Using Wirelessly Transmitted Power, and External Driving Device Thereof. WO Patent Application WO/2018/038304 A1, 2018US Patent Application US20190183665A1, 2019)

Startup Companies